Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Tumor Necrosis Factor Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Tumor Necrosis Factor Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
Tumor necrosis factor (TNF, cachexin or cachectin formerly known as tumor necrosis factor alpha or TNF-α) is an adipokine and a cytokine. TNF is a member of the TNF superfamily, which consists of various transmembrane proteins with a homologous TNF domain. As an adipokine, TNF promotes insulin resistance and is associated with obesity-induced type 2 diabetes. As a cytokine, TNF is used by the immune system for cell signaling. If macrophages (certain white blood cells) detect an infection, they release TNF to alert other immune system cells as part of an inflammatory response. There are two receptors for TNF, namely TNF receptor 1 (TNFR-1, p55 receptor) and TNFR-2 (p75 receptor). TNFR-1 is ubiquitously expressed while TNFR-2 is mainly expressed in immune cells. The mechanism of action (MOA) of the TNF inhibitors is binding to soluble TNF or inhibiting the interaction between TNF and its receptors. This binding prevents TNF from exerting its pro-inflammatory effects and reduces the inflammatory response in the body.
TNF inhibitors are used in the treatment of digestive system diseases, autoimmune diseases, intestinal diseases, connective tissue diseases, skin diseases, bone diseases, spondylitis, psoriasis, urologic diseases, kidney diseases, metabolic diseases, neoplasms, etc. Increased prevalence of inflammatory conditions, such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, inflammatory bowel disease, and the rise in the aging population, etc. are the key drivers for the TNF inhibitor market. For instance, according to the Centers for Disease Control and Prevention, an estimated 1.3% of US adults (3 million) reported being diagnosed with IBD, either Crohn's disease or ulcerative colitis. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in TNF inhibitors. For instance, Janssen Biotech’s Tecvayli (Teclistamab) was launched for the treatment of multiple myeloma. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Pfizer’s Elranatamab (PF-06863135) for the indication of multiple myeloma is under the various stages of clinical studies.
TNF Market Key Developments:
Approved Drug Molecules and Brand Names for TNF:
Drugs under the Pipeline for TNF:
Clinical Activity and Developments of TNF:
Up until July 2023, there will be about 40 companies with over 330 compounds that focus on various forms of rheumatoid arthritis, psoriasis, and ankylosing spondylitis. For these molecules, more than 3,000 clinical trials are being conducted and the majority are in phase-2, and phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Hyrimoz (Adalimumab-Adaz) |
14 |
|
Renflexis (Infliximab-Abda) |
13 |
|
Elranatamab (PF-06863135) |
15 |
|
Remsima SC (Infliximab Biosimilar SC) |
12 |
|
Orismilast Oral (LEO 32731) |
12 |
The molecules such as Humira (Adalimumab) developed by AbbVie for the line of treatment for the treatment of ulcerative colitis in patients 5 years of age and older, moderate to severe hidradenitis suppurative (HS) in patients 12 years and older, uveitis in patients 2 years of age and older, symptoms of active arthritis in patients with psoriatic arthritis, active ankylosing spondylitis, etc. Moreover, Janssen Biotech’s Tecvayli (Teclistamab) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Total sales of AbbVie’s Humira (Adalimumab) for the full year ended were US$58 billion in FY 2022 globally. Shows a 2.6% increase in the same period 2021. While the US experienced a 7.4% increase in sales annually and internationally, revenue decreased 22.2%, attributed to biosimilar competition. To date, Humira has pulled in sales of $214.2 billion for AbbVie (and previously Abbott) since its launch in 2003, making it the bestselling drug ever. However, In January 2023, Amgen became the first company to eye a slice of Humira’s American presence with the launch of the first Adalimumab biosimilar, Amjevita. While Amgen has the advantage of being first to market through a 2017 settlement with AbbVie, there are nine other players with approved biosimilars lined up - Alvotech, Amgen, Boehringer Ingelheim, Coherus, Fresenius Kabi, Mylan, Pfizer, Organon, Sandoz, Viatris. Increase incidence of inflammatory diseases like arthritis and ankylosing spondylitis seems to create lucrative opportunities for the TNF inhibitor market for the forecasted period.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Humira (Adalimumab), Tecvayli (Teclistamab),Remicade (Infliximab), Enbrel (Etanercept), etc are the few FDA approved TNF Inhibitors.
Total sales of AbbVie’s Humira (Adalimumab) for the full year ended were US$ 58 billion in FY 2022 in globally.
Eisai, AbbVie, Merck (MSD), J&J, Pfizer, Amgen, etc. are a few leading market players in the TNF market.
digestive system diseases, autoimmune diseases, intestinal diseases, connective tissue diseases, skin diseases, bone diseases, spondylitis, psoriasis, etc. are the major indications of TNF inhibitors.
There are a total of 159 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.